Renal interstitial arteriosclerotic lesions in lupus nephritis patients: A cohort study from China

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Huang, Jing ^a,b,c   Han, Sha Sha ^a,b,c   Qin, Dan Dan ^d   Wu, Li Hua ^e   Song, Yan ^f   Yu, Feng ^a,b,c   Wang, Su Xia ^a,b,c   Liu, Gang ^a,b,c   Zhao, Ming Hui ^a,b,c,g  

^a PEKING UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e NINGXIA MEDICAL UNIVERSITY   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

^g Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LEFLUNOMIDE; MYCOPHENOLATE MOFETIL; PREDNISONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINA; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNE COMPLEX DISEASE; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; OUTCOME ASSESSMENT; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; ADOLESCENT; AGED; ARTERIOSCLEROSIS; CHILD; COMPLICATION; IMMUNOLOGY; KIDNEY; LUPUS NEPHRITIS; MIDDLE AGED; PROGNOSIS; RISK; VASCULARIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ARTERIOSCLEROSIS; BEIJING; CHILD; COHORT STUDIES; FEMALE; HUMANS; KIDNEY; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; YOUNG ADULT;

EID: 84952662287     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141547     Document Type: Article

References (42)

1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients. Medicine (Baltimore) 2003;82:299-308.
2. Rosner S, Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, et al. A multicenter study of outcome in systemic lupus erythematosus. Arthritis Rheum 1982;25:601-11.
3. Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 2007;16:28-34.
4. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994;21:1264-1267.
5. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-2415.
6. Cervera R, Abarca-Costalago M, Abramovicz D, Allegri F, Annunziata P, Aydintug AO, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". Autoimmun Rev 2006;5:180-186. PMID: 16483917
7. Cervera R, Font J, Shoenfeld Y; European Working Party on Systemic Lupus Erythematosus. European Working Party on Systemic Lupus Erythematosus: a 15-year report. Autoimmun Rev 2006;5:549-553. PMID: 17027891
8. Banfi G, Bertani T, Boeri V, Faraggiana T, Mazzucco G, Monga G, et al. Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 1991;18:240-8.
9. Grishman E, Venkataseshan VS. Vascular lesions in lupus nephritis. Mod Pathol 1988;1:235-241.
10. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-530.
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
12. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-695.
13. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45:544-550.
14. Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994;4:1499-1515.
15. Descombes E, Droz D, Drouet L, Grünfeld JP, Lesavre P. Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997;76:355-368.
16. Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013;83:715-723.
17. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-1118.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-640.
19. D'Agostino RB Sr1, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General Cardiovascular Risk Profile for Use in Primary Care The Framingham Heart Study. Circulation 2008;117:743-753.
20. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003;108:1146-1162.
21. Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007;16:707-712.
22. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-272.
23. Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008;17:638-644.
24. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-980.
25. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-742.
26. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;4:368:1279-1290.
27. McMahon M, Hahn BH. Atherosclerosis and Systemic Lupus Erythematosus-Mechanistic Basis of the Association. Curr Opin Immunol. 2007;19:633-639. PMID: 18083018
28. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert A. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation. 2000;102:2576-2581. PMID: 11085959
29. Urowitz MB, Bookman AA, Koehler BE, Grdon DA, Smythe HA, Ogryzlo MA. et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-225.
30. de Leeuw K, Smit AJ, de Groot E, van Roon AM, Kallenberg CG, Bijl M. Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. Atherosclerosis 2009;206:546-550.
31. Berden JH. Lupus nephritis. Kidney Int 1997;52:538-558.
32. Lewis MJ, Malik TH, Fossati-Jimack L, Carassiti D, Cook HT, Haskard DO, et al. Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia. Arthritis Rheum 2012;64:2707-2718
33. Jonsson H, Nived O, Srurfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989;68:141-150.
34. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012;308:2349-2360.
35. Inoue T, Ogawa T, Iwabuchi Y, Otsuka K, Nitta K. Left ventricular end-diastolic diameter is an independent predictor of mortality in hemodialysis patients. Ther ApherDial. 2012;16:134-141.
36. Sun W, Jiao Y, Cui B, Gao X, Xia Y, Zhao Y. Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Laboratory investigation; a journal of technical methods and pathology. 2013;93:626-638. doi:10.1038/labinvest.2013.61 PMID: 23628898
37. Zhang JJ, Jiang L, Liu G, Wang SX, Zou WZ, Zhang H, et al. Elevation of serum von Willebrand factor and anti-endothelial cell antibodies in patients with immunoglobulin A nephropathy are associated with intrarenal arterial lesions. Nephrology 2008;13:712-720. doi:10.1111/j.1440-1797.2008.00983.x PMID: 18771467
38. Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus. 2011;20:5-13. doi:10.1177/0961203310382429 PMID: 21138982
39. Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-Giri A, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis and rheumatism. 2012;64:2975-85. doi:10.1002/art.34504 PMID: 22549550
40. Mattos P, Santiago MB. Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review. Clinical rheumatology. 2011;30:1651-71.
41. Andreoli L, Fredi M, Nalli C, Piantoni S, Reggia R, Dall'Ara F, et al. Clinical significance of IgA anti-cardiolipin and IgA anti-beta2glycoprotein I antibodies. Current rheumatology reports. 2013;15:343. doi:10. 1007/s11926-013-0343-1 PMID: 23754504
42. Griffin B, Lightstone L. Renoprotective strategies in lupus nephritis: beyond immunosuppression. Lupus 2013;22:1267-1273.